Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process

作者：Escalona Rayo Oscar; Fuentes Vazquez Paulina; Leyva Gomez Gerardo; Cisneros Bulmaro; Villalobos Rafael; Magana Jonathan J; Quintanar Guerrero David

来源：Drug Development and Industrial Pharmacy, 2017, 43(6): 871-888.

DOI：10.1080/03639045.2017.1281949

• PolyQ diseases
• protein aggregation
• therapeutic agents
• brain
• blood-brain barrier
• nanotechnology
• nanoparticulate systems

Polyglutamine (polyQ) diseases are a class of neurodegenerative disorders that cause cellular dysfunction and, eventually, neuronal death in specific regions of the brain. Neurodegeneration is linked to the mis-folding and aggregation of expanded polyQ-containing proteins, and their inhibition is one of major therapeutic strategies used commonly. However, successful treatment has been limited to date because of the intrinsic properties of therapeutic agents (poor water solubility, low bioavailability, poor pharmacokinetic properties), and difficulty in crossing physiological barriers, including the blood-brain barrier (BBB). In order to solve these problems, nanoparticulate systems with dimensions of 1-1000nm able to incorporate small and macromolecules with therapeutic value, to protect and deliver them directly to the brain, have recently been developed, but their use for targeting polyQ disease-mediated protein misfolding and aggregation remains scarce. This review provides an update of the polyQ protein aggregation process and the development of therapeutic strategies for halting it. The main features that a nanoparticulate system should possess in order to enhance brain delivery are discussed, as well as the different types of materials utilized to produce them. The final part of this review focuses on the potential application of nanoparticulate system strategies to improve the specific and efficient delivery of therapeutic agents to the brain for the treatment of polyQ diseases.

• 出版日期2017-6